In This Article:
As European markets continue to rally, driven by slowing inflation and optimistic economic sentiment, investors are increasingly looking toward growth opportunities in stable economies like Sweden. In this environment, stocks with high insider ownership can be particularly appealing as they often indicate strong confidence from those closest to the company.
Top 10 Growth Companies With High Insider Ownership In Sweden
| Name | Insider Ownership | Earnings Growth |
| CTT Systems (OM:CTT) | 16.9% | 24.8% |
| Truecaller (OM:TRUE B) | 29.5% | 21.6% |
| Fortnox (OM:FNOX) | 21.1% | 22.6% |
| Magle Chemoswed Holding (OM:MAGLE) | 14.9% | 72.2% |
| Biovica International (OM:BIOVIC B) | 18.8% | 73.1% |
| BioArctic (OM:BIOA B) | 34% | 98.4% |
| Yubico (OM:YUBICO) | 37.5% | 42.5% |
| KebNi (OM:KEBNI B) | 37.8% | 86.1% |
| InCoax Networks (OM:INCOAX) | 19% | 115.5% |
| Calliditas Therapeutics (OM:CALTX) | 12.7% | 51.9% |
Here we highlight a subset of our preferred stocks from the screener.
Medicover
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Medicover AB (publ) offers healthcare and diagnostic services in Poland, Sweden, and internationally, with a market cap of SEK28.32 billion.
Operations: The company's revenue is primarily derived from Healthcare Services (€1.32 billion) and Diagnostic Services (€610 million).
Insider Ownership: 11.1%
Medicover, a growth company with high insider ownership in Sweden, recently announced revenue guidance exceeding €2.2 billion for year-end 2025 and reported strong earnings growth, with second-quarter sales of €509.4 million and net income of €6.3 million. The company is expected to see significant annual profit growth at 38.6%, outpacing the Swedish market's forecasted 15.1%. With no substantial insider selling and new CFO Anand Patel joining soon, Medicover remains well-positioned for future expansion despite interest payments not being well covered by earnings.
-
Delve into the full analysis future growth report here for a deeper understanding of Medicover.
-
The valuation report we've compiled suggests that Medicover's current price could be inflated.
Vimian Group
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Vimian Group AB (publ) operates in the global animal health sector and has a market capitalization of SEK22.47 billion.
Operations: Vimian Group AB (publ) generates revenue from four primary segments: Medtech (€111.91 million), Diagnostics (€20.63 million), Specialty Pharma (€158.39 million), and Veterinary Services (€53.95 million).
Insider Ownership: 11.1%
Vimian Group, characterized by high insider ownership, reported second-quarter sales of €90.99 million and net income of €4.87 million, showing year-over-year growth. Earnings are forecast to grow significantly at 62.89% annually over the next three years, outpacing the Swedish market's 15.1%. Despite trading at 30.3% below fair value and having substantial insider buying recently, revenue growth is expected to be slower than 20% per year but faster than the market average of 0.9%.